- Home
- NMFC vs SANA Comparison
NMFC vs SANA Comparison
Compare NMFC & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMFC
- SANA
- Stock Information
- Founded
- NMFC 2010
- SANA 2018
- Country
- NMFC United States
- SANA United States
- Employees
- NMFC N/A
- SANA N/A
- Industry
- NMFC Finance/Investors Services
- SANA Medicinal Chemicals and Botanical Products
- Sector
- NMFC Finance
- SANA Health Care
- Exchange
- NMFC Nasdaq
- SANA Nasdaq
- Market Cap
- NMFC 1.2B
- SANA 983.4M
- IPO Year
- NMFC 2011
- SANA 2021
- Fundamental
- Price
- NMFC $8.98
- SANA $4.51
- Analyst Decision
- NMFC Hold
- SANA Strong Buy
- Analyst Count
- NMFC 3
- SANA 6
- Target Price
- NMFC $10.33
- SANA $8.00
- AVG Volume (30 Days)
- NMFC 991.5K
- SANA 3.8M
- Earning Date
- NMFC 11-03-2025
- SANA 11-07-2025
- Dividend Yield
- NMFC 14.22%
- SANA N/A
- EPS Growth
- NMFC N/A
- SANA N/A
- EPS
- NMFC 0.77
- SANA N/A
- Revenue
- NMFC $355,675,000.00
- SANA N/A
- Revenue This Year
- NMFC N/A
- SANA N/A
- Revenue Next Year
- NMFC N/A
- SANA N/A
- P/E Ratio
- NMFC $11.73
- SANA N/A
- Revenue Growth
- NMFC N/A
- SANA N/A
- 52 Week Low
- NMFC $8.84
- SANA $1.26
- 52 Week High
- NMFC $12.05
- SANA $7.30
- Technical
- Relative Strength Index (RSI)
- NMFC 22.95
- SANA 72.37
- Support Level
- NMFC $9.46
- SANA $4.00
- Resistance Level
- NMFC $9.67
- SANA $4.82
- Average True Range (ATR)
- NMFC 0.19
- SANA 0.26
- MACD
- NMFC -0.05
- SANA 0.13
- Stochastic Oscillator
- NMFC 0.52
- SANA 83.07
About NMFC New Mountain Finance Corporation
New Mountain Finance Corp is a closed-end, non-diversified management investment company. It invests in equity interests such as preferred stock, common stock, warrants, or options received in connection with debt investments or may include direct investment in the equity of private companies. The company's investment objective is to generate current income and capital appreciation through sourcing and origination of debt securities at all levels of the capital structure, including first and second-lien debt, notes, bonds and mezzanine securities.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.